After a single subcutaneous dose AVE5026 is completely absorbed with a bioavailability of 98% compared with intravenous administration. The drug has a linear pharmacokinetic profile and after repeated dosing in elderly subjects a slight increase in accumulation of this agent was seen reflecting renal impairment [62]. In the phase II, parallel-group, double-blind, double-dummy, #links# TREK study,


Who Upvoted this Story

Social Bookmarking Sites
What is Kliqqi?

Kliqqi is an open source content management system that lets you easily create your own user-powered website.

Latest Comments